LFTD Partners (LIFD)
OTHER OTC:LIFD
Want to see LIFD full AI Analyst Report?
Top Page
LFTD Partners
(OTC:LIFD)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.18
▼(-41.33% Downside)
Action:Reiterated
Date:05/15/26
The score is weighed down primarily by sharply weakened profitability and large recent losses, alongside weak technical momentum (price below major moving averages and negative MACD). Positive TTM operating/free cash flow and low reported leverage provide some support, but a negative P/E and no dividend yield data limit valuation-based upside.
Positive Factors
Low Leverage / Balance Sheet Flexibility
Debt-to-equity near 0.14 gives the company meaningful balance-sheet flexibility, lowering refinancing and interest burdens. That capacity supports sustaining operations, funding working capital or targeted R&D during a multi-month turnaround window without immediate external financing.
Negative Factors
Deeply Negative Profitability
A net margin near -67% indicates severe unprofitability that erodes equity and limits reinvestment. Such deep losses constrain management’s ability to invest in growth or absorb shocks, raising the likelihood that structural cost or revenue changes are needed to restore sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet Flexibility
Debt-to-equity near 0.14 gives the company meaningful balance-sheet flexibility, lowering refinancing and interest burdens. That capacity supports sustaining operations, funding working capital or targeted R&D during a multi-month turnaround window without immediate external financing.
Read all positive factors
LFTD Partners (LIFD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.67M
Dividend YieldN/A
Average Volume (3M)1.38K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth3.28%
EPS Growth-2712.77%
CountryUS
Employees148
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding14,822,678
10 Day Avg. Volume3,614
30 Day Avg. Volume1,380
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.08
P/FCF Ratio<0.01
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue0.06
Enterprise Value/Gross Profit0.28
Enterprise Value/Ebitda-0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LFTD Partners Business Overview & Revenue Model
Company Description
LFTD Partners Inc., through its subsidiary, Lifted Made, manufactures and sells psychedelic products under its Silly Shruum brand and hemp-derived cannabinoid products under its Urb Finest Flowers brand. The company was formerly known as Acquired ...
LFTD Partners Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.96M | 36.92M | 37.33M | 51.61M | 57.42M | 31.66M |
| Gross Profit | 8.39M | 12.37M | 12.75M | 19.70M | 20.99M | 15.94M |
| EBITDA | -27.71M | -23.59M | -1.50M | 3.35M | 10.31M | 7.40M |
| Net Income | -28.72M | -24.86M | -1.86M | 2.16M | 7.20M | 5.80M |
Balance Sheet | ||||||
| Total Assets | 14.60M | 19.27M | 47.32M | 51.35M | 41.13M | 39.42M |
| Cash, Cash Equivalents and Short-Term Investments | 2.09M | 1.77M | 2.15M | 4.36M | 3.72M | 1.60M |
| Total Debt | 1.76M | 1.76M | 4.51M | 4.49M | 1.86M | 1.34M |
| Total Liabilities | 6.14M | 6.64M | 9.81M | 12.53M | 6.59M | 11.96M |
| Stockholders Equity | 8.47M | 12.63M | 37.50M | 38.82M | 34.54M | 27.46M |
Cash Flow | ||||||
| Free Cash Flow | 1.26M | 1.20T | -1.27M | -150.74K | 2.12M | 5.25M |
| Operating Cash Flow | 1.43M | 1.32T | -960.07K | 638.92K | 3.04M | 5.62M |
| Investing Cash Flow | -164.17K | -121.64B | -479.57K | -2.52M | -916.12K | -446.65K |
| Financing Cash Flow | -2.45M | -2.58T | -770.95K | 3.70M | -193.42K | -4.01M |
LFTD Partners Technical Analysis
Negative
0.30
Price Trends
0.21
Negative
0.22
Negative
0.24
Negative
Market Momentum
>-0.01
Negative
18.71
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIFD, the sentiment is Negative. The current price of 0.3 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.21, and above the 200-day MA of 0.24, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 18.71 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LIFD.
LFTD Partners Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $36.97M | -0.72 | -122.57% | ― | -100.00% | 54.21% | |
47 Neutral | $7.87M | -2.84 | -40.66% | ― | 2.00% | 94.31% | |
45 Neutral | $2.67M | -0.09 | -2.05% | ― | 3.28% | -2712.77% | |
42 Neutral | $1.83M | -14.53 | -93.87% | ― | -6.14% | -24.22% |
* Healthcare Sector Average
LIFD
LFTD Partners
0.18
-0.21
-53.85%
YCBD
cbdMD
0.72
-0.24
-24.69%
IMCC
IM Cannabis Corp
0.27
-2.49
-90.11%
IXHL
Incannex Healthcare Limited Sponsored ADR
2.92
-2.46
-45.70%
AKAN
Akanda Corp
15.63
-80.00
-83.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.